Characterization of antibodies submitted to the B cell section of the 8th Human Leukocyte Differentiation Antigens Workshop by flow cytometry and immunohistochemistry

Cell Immunol. Jul-Aug 2005;236(1-2):6-16. doi: 10.1016/j.cellimm.2005.08.002. Epub 2005 Sep 12.

Abstract

The aim of this study was to characterize the reactivity of monoclonal antibodies (mAbs) that had been submitted to the HLDA8 Workshop. The lineage specificity of target molecules was tested by analyzing their expression patterns on blood cells, leukocytes, and lymphocyte subsets. The expression of target molecules during B cell development, ranging from early precursors to plasma cells, was analyzed using a large panel of B cell lines. Our results have permitted us to characterize the expression of 10 new CD molecules: CD316 (HM1.24, BST2), CD268 (BAFF-R, TNFRSF13C), CD269 (BCMA, TNFRF17), CD267 (TACI, TNFRSF13B), CD275 (ICOSL, B7H2), CD254 (TRANCE, TNFSF11), CD252 (OX40L TNFSF4), CD315 (CD9-P), CD316 (EWI-2, PGRL), and CD307 (IRTA-2 or FcRH5). Three of these new CDs, CD267, CD269, and CD307 presented a B cell-restricted expression pattern. MAbs against these novel cell-surface molecules may offer new tools for research, diagnosis, and therapy.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology*
  • Antibody Specificity
  • Antigens, CD / analysis
  • B-Lymphocytes / immunology*
  • Cell Lineage / immunology
  • Cells, Cultured
  • Flow Cytometry
  • HLA-D Antigens / immunology
  • Immunohistochemistry
  • Membrane Proteins / analysis
  • Mice
  • Rats
  • Receptors, Tumor Necrosis Factor / analysis
  • Transmembrane Activator and CAML Interactor Protein

Substances

  • Antibodies, Monoclonal
  • Antigens, CD
  • HLA-D Antigens
  • Membrane Proteins
  • Receptors, Tumor Necrosis Factor
  • TNFRSF13B protein, human
  • Transmembrane Activator and CAML Interactor Protein